{"name": "Genocea Biosciences",
 "permalink": "genocea-biosciences",
 "crunchbase_url": "http://www.crunchbase.com/company/genocea-biosciences",
 "homepage_url": "http://www.genocea.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2006,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "website.inquiry@genocea.com",
 "phone_number": "617.876.8191",
 "description": "",
 "created_at": "Thu Aug 19 02:27:44 UTC 2010",
 "updated_at": "Thu Oct 11 03:37:46 UTC 2012",
 "overview": "\u003Cp\u003EGenocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations.  Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Streptococcus pneumoniae, and Chlamydia trachomatis,  infections that affect hundreds of millions of people worldwide. The company expects to begin clinical trials for its lead program, a therapeutic vaccine for HSV-2, in early 2011.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       63],
      "assets/images/resized/0009/8416/98416v1-max-150x150.png"],
     [[250,
       106],
      "assets/images/resized/0009/8416/98416v1-max-250x250.png"],
     [[256,
       109],
      "assets/images/resized/0009/8416/98416v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Rob",
      "last_name": "Paull",
      "permalink": "rob-paull",
      "image": null}},
   {"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Chip",
      "last_name": "Clark",
      "permalink": "chip-clark",
      "image": null}},
   {"is_past": false,
    "title": "Co-founder",
    "person":
     {"first_name": "Kevin",
      "last_name": "Bitterman",
      "permalink": "kevin-bitterman",
      "image":
       {"available_sizes":
         [[[100,
            150],
           "assets/images/resized/0025/1971/251971v1-max-150x150.jpg"],
          [[150,
            225],
           "assets/images/resized/0025/1971/251971v1-max-250x250.jpg"],
          [[150,
            225],
           "assets/images/resized/0025/1971/251971v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Ling",
      "last_name": "Wong",
      "permalink": "ling-wong",
      "image": null}},
   {"is_past": false,
    "title": "Director ",
    "person":
     {"first_name": "Kevin",
      "last_name": "Bitterman",
      "permalink": "kevin-bitterman",
      "image":
       {"available_sizes":
         [[[100,
            150],
           "assets/images/resized/0025/1971/251971v1-max-150x150.jpg"],
          [[150,
            225],
           "assets/images/resized/0025/1971/251971v1-max-250x250.jpg"],
          [[150,
            225],
           "assets/images/resized/0025/1971/251971v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$65M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.finsmes.com/2011/01/genocea-biosciences-closes-35m-series-b.html",
    "source_description": "Genocea Biosciences Closes $35M Series B Financing Round",
    "raised_amount": 35000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 1,
    "funded_day": 3,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Johnson \u0026 Johnson Development",
         "permalink": "johnson-johnson-development",
         "image":
          {"available_sizes":
            [[[150,
               61],
              "assets/images/resized/0003/2806/32806v1-max-150x150.png"],
             [[206,
               85],
              "assets/images/resized/0003/2806/32806v1-max-250x250.png"],
             [[206,
               85],
              "assets/images/resized/0003/2806/32806v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Skyline Ventures",
         "permalink": "skyline-ventures",
         "image":
          {"available_sizes":
            [[[150,
               53],
              "assets/images/resized/0025/1697/251697v1-max-150x150.png"],
             [[250,
               88],
              "assets/images/resized/0025/1697/251697v1-max-250x250.png"],
             [[300,
               106],
              "assets/images/resized/0025/1697/251697v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "MP Healthcare Venture Management",
         "permalink": "mp-healthcare-venture-management-inc",
         "image":
          {"available_sizes":
            [[[150,
               17],
              "assets/images/resized/0005/0688/50688v3-max-150x150.png"],
             [[250,
               29],
              "assets/images/resized/0005/0688/50688v3-max-250x250.png"],
             [[450,
               52],
              "assets/images/resized/0005/0688/50688v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Polaris Partners",
         "permalink": "polaris-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0001/1153/11153v1-max-150x150.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-250x250.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Lux Capital",
         "permalink": "lux-capital",
         "image":
          {"available_sizes":
            [[[150,
               54],
              "assets/images/resized/0004/3976/43976v1-max-150x150.png"],
             [[250,
               90],
              "assets/images/resized/0004/3976/43976v1-max-250x250.png"],
             [[261,
               94],
              "assets/images/resized/0004/3976/43976v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "SR One",
         "permalink": "sr-one",
         "image":
          {"available_sizes":
            [[[150,
               58],
              "assets/images/resized/0004/8794/48794v2-max-150x150.jpg"],
             [[206,
               81],
              "assets/images/resized/0004/8794/48794v2-max-250x250.jpg"],
             [[206,
               81],
              "assets/images/resized/0004/8794/48794v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Cycad Group",
         "permalink": "cycad-group",
         "image":
          {"available_sizes":
            [[[131,
               150],
              "assets/images/resized/0018/2602/182602v1-max-150x150.jpg"],
             [[158,
               180],
              "assets/images/resized/0018/2602/182602v1-max-250x250.jpg"],
             [[158,
               180],
              "assets/images/resized/0018/2602/182602v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Auriga Partners",
         "permalink": "auriga-partners",
         "image":
          {"available_sizes":
            [[[150,
               104],
              "assets/images/resized/0003/9844/39844v2-max-150x150.png"],
             [[250,
               173],
              "assets/images/resized/0003/9844/39844v2-max-250x250.png"],
             [[335,
               233],
              "assets/images/resized/0003/9844/39844v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Morningside Venture Investments",
         "permalink": "morningside-venture-investments",
         "image": null},
       "person": null}]},
   {"round_code": "c",
    "source_url": "http://www.masshightech.com/stories/2012/10/08/daily28-Genocea-raises-30M-to-advance-herpes-vaccine.html",
    "source_description": "Genocea raises $30M to advance herpes vaccine",
    "raised_amount": 30000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 10,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Gates Foundation",
         "permalink": "gates-foundation",
         "image":
          {"available_sizes":
            [[[150,
               30],
              "assets/images/resized/0008/4159/84159v1-max-150x150.png"],
             [[250,
               50],
              "assets/images/resized/0008/4159/84159v1-max-250x250.png"],
             [[259,
               52],
              "assets/images/resized/0008/4159/84159v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Polaris Partners",
         "permalink": "polaris-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0001/1153/11153v1-max-150x150.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-250x250.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Lux Capital",
         "permalink": "lux-capital",
         "image":
          {"available_sizes":
            [[[150,
               54],
              "assets/images/resized/0004/3976/43976v1-max-150x150.png"],
             [[250,
               90],
              "assets/images/resized/0004/3976/43976v1-max-250x250.png"],
             [[261,
               94],
              "assets/images/resized/0004/3976/43976v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "SR One",
         "permalink": "sr-one",
         "image":
          {"available_sizes":
            [[[150,
               58],
              "assets/images/resized/0004/8794/48794v2-max-150x150.jpg"],
             [[206,
               81],
              "assets/images/resized/0004/8794/48794v2-max-250x250.jpg"],
             [[206,
               81],
              "assets/images/resized/0004/8794/48794v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Johnson \u0026 Johnson Development Corporation",
         "permalink": "johnson-johnson-development-corporation",
         "image":
          {"available_sizes":
            [[[150,
               57],
              "assets/images/resized/0005/8402/58402v1-max-150x150.png"],
             [[225,
               86],
              "assets/images/resized/0005/8402/58402v1-max-250x250.png"],
             [[225,
               86],
              "assets/images/resized/0005/8402/58402v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Skyline Ventures",
         "permalink": "skyline-ventures",
         "image":
          {"available_sizes":
            [[[150,
               53],
              "assets/images/resized/0025/1697/251697v1-max-150x150.png"],
             [[250,
               88],
              "assets/images/resized/0025/1697/251697v1-max-250x250.png"],
             [[300,
               106],
              "assets/images/resized/0025/1697/251697v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Cycad Group",
         "permalink": "cycad-group",
         "image":
          {"available_sizes":
            [[[131,
               150],
              "assets/images/resized/0018/2602/182602v1-max-150x150.jpg"],
             [[158,
               180],
              "assets/images/resized/0018/2602/182602v1-max-250x250.jpg"],
             [[158,
               180],
              "assets/images/resized/0018/2602/182602v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Auriga Partners",
         "permalink": "auriga-partners",
         "image":
          {"available_sizes":
            [[[150,
               104],
              "assets/images/resized/0003/9844/39844v2-max-150x150.png"],
             [[250,
               173],
              "assets/images/resized/0003/9844/39844v2-max-250x250.png"],
             [[335,
               233],
              "assets/images/resized/0003/9844/39844v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "MP Healthcare Venture Management",
         "permalink": "mp-healthcare-venture-management-inc",
         "image":
          {"available_sizes":
            [[[150,
               17],
              "assets/images/resized/0005/0688/50688v3-max-150x150.png"],
             [[250,
               29],
              "assets/images/resized/0005/0688/50688v3-max-250x250.png"],
             [[450,
               52],
              "assets/images/resized/0005/0688/50688v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Morningside Venture Investments",
         "permalink": "morningside-venture-investments",
         "image": null},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "161 First St.",
    "address2": "Suite 2C",
    "zip_code": "02142",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "nine venture capitalists, including three new ones, invested $35 million in a Series B round",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 5,
    "source_url": "http://www.masshightech.com/stories/2011/01/03/daily37-Genoceas-35M-VC-round-pushing-herpes-vaccine-toward-clinic-.html",
    "source_text": null,
    "source_description": "Genocea's $35M VC round pushing herpes vaccine toward clinic",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genocea Biosciences",
      "permalink": "genocea-biosciences"}},
   {"description": "has promoted chief business officer Chip Clark to president and CEO",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2011/01/31/daily19-Clark-named-CEO-at-Genocea-Biosciences.html",
    "source_text": null,
    "source_description": "Clark named CEO at Genocea Biosciences",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genocea Biosciences",
      "permalink": "genocea-biosciences"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}